Canaccord Genuity Remains a Buy on Intersect ENT

By Ryan Adsit

In a report released today, Kyle Rose from Canaccord Genuity maintained a Buy rating on Intersect ENT (NASDAQ: XENT), with a price target of $37. The company’s shares opened today at $31.20, close to its 52-week high of $33.25.

According to TipRanks.com, Rose is a 5-star analyst with an average return of 12.6% and a 58.5% success rate. Rose covers the Healthcare sector, focusing on stocks such as Obalon Therapeutics Inc, Zimmer Biomet Holdings, and Stryker Corporation.

Intersect ENT has an analyst consensus of Strong Buy, with a price target consensus of $32.

The company has a one year high of $33.25 and a one year low of $7.65. Currently, Intersect ENT has an average volume of 323.4K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Intersect ENT, Inc. is a medical technology company, which is dedicated in the treatment of ear, nose, and throat conditions through evidence-based innovation, providing physicians with solutions to improve quality of life for patients. The company was founded by Donald J. Eaton in October 2003 and is headquartered in Menlo Park, CA.